We have recently demonstrated that multiple signalling pathways are involved in thrombin-induced proliferation in rat astrocytes. Thrombin acts by protease-activated receptor-1 (PAR-1) via mitogen-activated protein kinase activity. Signalling includes both G i /(bc subunits)-phosphatidylinositol 3-kinase and a G q -phospholipase C/Ca 2+ /protein kinase C (PKC) pathway. In the present study, we investigated the possible protein tyrosine kinases which might be involved in thrombin signalling cascades. We found that, in astrocytes, thrombin can evoke phosphorylation of proline-rich tyrosine kinase (Pyk2) via PAR-1. This process is dependent on the increase in intracellular Ca 2+ and PKC activity. Moreover, in response to thrombin stimulation Pyk2 formed a complex with Src tyrosine kinase and adapter protein growth factor receptorbound protein 2 (Grb2), which could be coprecipitated. Furthermore, both thrombin-induced Pyk2 phosphorylation and extracellular signal-regulated kinase (ERK) 1/2 phosphorylation can be attenuated by Src kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d]pyrimidine. From these data we conclude that PAR-1 uses Ca
Thrombin has been proven to act as a signalling molecule in astrocytes, inducing reversal of stellation, proliferation, synthesis and secretion of nerve growth factor and endothelin-1 (Ehrenreich et al. 1993; Neveu et al. 1993; Grabham and Cunningham 1995) , events that are associated with brain injury. These effects of thrombin are mediated via a cell surface G protein-coupled receptor (GPCR)-protease-activated receptor (PAR) (Coughlin 1994) . Thrombin activates its target receptor by cleaving the amino terminus of the receptor. A new amino terminus is exposed and binds as a tethered ligand to the body of the receptor to effect transmembrane signalling. In a similar way, PAR can also be activated by synthetic peptides which comprise the sequences of the tethered ligand. So far, four subtypes of PARs have been identified (PAR-1, -2, -3 and -4). Previously, we have demonstrated that cultured rat astrocytes functionally coexpress the four subtypes of PARs. Although thrombin can activate PAR-1, -3 and -4 in astrocytes (Wang et al. 2002a) , PAR-1 is the predominant receptor for regulating thrombin-induced proliferation (Wang et al. 2002b) .
Pathological development or traumatic injury in the CNS may stimulate astrocyte proliferation as part of the repair process and contribute to astrogliosis, which has been implicated in brain injury and also in neurodegenerative diseases, such as Alzheimer's disease (Griffin et al. 1989; Vaughan et al. 1994) . High concentrations of thrombin have often been observed in the brain after breakdown of the blood-brain barrier, thereby possibly causing astrogliosis. We made attempts to characterize the signalling pathway underlying thrombin-induced proliferation in astrocytes in our recent publication (Wang et al. 2002b) as reviewed in Hollenberg (2002) .
Investigating thrombin-induced signalling in astrocytes, we demonstrated that thrombin/PAR-1 delivers a mitogenic stimulus via extracellular signal-regulated kinase (ERK) 1/2 activation, which involves two pathways: firstly, a pertussis toxin-sensitive G protein-mediated phosphatidylinositol 3-kinase pathway and, secondly, a pertussis toxin-insensitive G protein-mediated phospholipase C (PLC)/Ca 2+ /protein kinase C (PKC) pathway. This signalling cascade, however, does not cross-talk with epidermal growth factor receptor, although accumulating data had suggested that part of the mitogenic stimulus of some GPCR agonists, such as thrombin, lysophosphatidic acid, endothelin and carbachol (Prenzel et al. 1999; Gschwind et al. 2001) , can be produced by transactivation of epidermal growth factor receptor (Carpenter 1999; Daub et al. 1996; Daub et al. 1997; Pierce et al. 2001) .
Proline-rich tyrosine kinase (Pyk2), also known as cell adhesion kinase b, calcium-dependent tyrosine kinase and related adhesion focal tyrosine kinase, is a novel nonreceptor tyrosine kinase with a high sequence homology to p125 focal adhesion kinase. Similar to focal adhesion kinase, Pyk2 has been shown to link GPCRs to ERK1/2 activation by recruiting the intermediates such as growth factor receptor-bound protein 2 (Grb2), adapter protein in the Ras (small GTPase) pathway (Shc) and the nucleotide exchange factor Sos (son of sevenless; Ras guanine nucleotide-releasing factor) (Lev et al. 1995) . Moreover, Pyk2 seems to operate in concert with c-Src Della Rocca et al. 1997) .
Pyk2 has attracted a great deal of attention because of its sensitivity to increased intracellular free Ca 2+ levels (Avraham et al. 1995; Lev et al. 1995; Sasaki et al. 1995) . While usually mainly distributed diffusely throughout the cytoplasm, Pyk2 is readily activated by various stimuli, including growth factors, neurotransmitters, adhesion to the extracellular matrix and stress signals Cazaubon et al. 1997; Felsch et al. 1998; Litvak et al. 2000) , which increase intracellular calcium concentration and/or activate PKC. As Ca 2+ is known to be an important intracellular messenger to control cellular processes as diverse as cell proliferation, neuronal plasticity or cell death (Berridge et al. 1998) , Pyk2 has the potential to play a significant role in the transmission and regulation of cellular signals.
It has been described in some cell types that Pyk2 phosphorylation depends both on the increase in intracellular Ca 2+ and activation of PKC (Lev et al. 1995; Schaller and Sasaki 1997; Sabri et al. 1998; Wu et al. 2002) . In human endothelial cells, however, thrombin-stimulated Pyk2 phosphorylation is dependent on intracellular Ca 2+ but independent of PKC and Src kinases (Keogh et al. 2002) . Ca 2+ and PKC have been implicated in our previous study as playing an important role in regulating thrombin-induced mitogenesis via ERK1/2 pathway (Wang et al. 2002b) . However, it is still unknown whether Pyk2, the important calcium-dependent tyrosine kinase, might also be involved in thrombin signalling cascades in astrocytes. In the present study, we examined this possibility and came to the conclusion that thrombin can indeed induce Pyk2 activation in astrocytes in a Ca 2+ -and PKC-dependent manner, which is associated with Src and Grb2, leading to ERK1/2 phosphorylation.
Materials and methods

Materials
Human thrombin and protein G-agarose were from Sigma (St Louis, MO, USA). The synthetic thrombin receptor agonist peptide (TRag, Ala-parafluorPhe-Arg-Cha-homoArg-Tyr-NH 2 ) was purchased from Neosystem Laboratoire (Strasbourg, France). 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (PP2) was from Tocris (Ellisville, MO, USA). U73122, 2-aminoethoxydiphenylborate (2-APB) and phorbol-12,13-dibutyrate (PDBu) were purchased from Calbiochem (La Jolla, CA, USA) and bisindolylmaleimide (GF-109203X) was from LC Laboratories (Grünberg, Germany). Anti-Pyk2/cell adhesion kinase b monoclonal antibody (clone 74), anti-phosphotyrosine monoclonal antibody (clone 4G10), anti-Shc polyclonal antibody, anti-Src monoclonal antibody (clone GD11) and agarose-conjugated glutathione-S-transferase (GST)-Grb2 fusion protein were from Upstate Biotechnology (Lake Placid, NY, USA). Anti-phospho-Src (Tyr418) polyclonal antibody, antiphospho-Pyk2 (Tyr402) polyclonal antibody and anti-phospho-Pyk2 (Tyr881) polyclonal antibody were from Biosource International, Camarillo, CA, USA. Anti-phospho-p44/42 mitogen-activated protein kinase (MAPK; Thr202/Tyr204) E10 monoclonal antibody and anti-p44/42 MAPK antibody were from New England Biolabs, Beverly, MA, USA. Horseradish peroxidase-conjugated secondary antibodies were from Dianova (Hamburg, Germany).
Cell cultures
Primary astrocyte cell cultures were obtained from two new-born rats according to a previously published method (Ubl and Reiser 1997) . All experiments conformed to guidelines from SachsenAnhalt, Germany on the ethical use of animals and all efforts were made to minimize the number of animals used. In brief, new-born rats were decapitated, total brains were removed and collected in ice-cold Puck's-D1 solution composed of (mM): NaCl, 137.0; KCl, 5.4; KH 2 PO 4 , 0.2; Na 2 HPO 4 , 0.17; glucose, 5.0 and sucrose, 58.4, pH 7.4. The brains were gently passed through nylon mesh (136 lm pore width) and centrifuged at 4°C for 5 min at 500 g. The cells were resuspended in 10 mL Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal calf serum, 20 U/mL penicillin and 20 lg/mL streptomycin (Biochrom, Berlin, Germany). The cells were plated on round coverslips (22 mm diameter) placed in culture dishes (50 mm diameter) at a density of 2.5-5.0 · 10 5 cells/dish and incubated at 37°C with 10% CO 2 , humidified to saturation. The medium was changed for the first time after 5 days and thereafter every 2-3 days, depending on the cell density. For experiments, cells were used between days 7 and 14 in culture. The purity of astrocyte culture was determined by immunofluorescence using a mouse monoclonal antibody against glial fibrillary acidic protein (Boehringer, Mannheim, Germany), an astrocyte-specific marker. AlexaÔ 488 anti-mouse IgG antibody (Molecular Probes, Eugene, OR, USA) was used as the secondary antibody. Confluent monolayers of astrocytes showed > 97% positive staining for glial fibrillary acidic protein.
ERK1/2 phosphorylation
Confluent cells were deprived of serum for 24 h before use and drug treatments carried out at 37°C as indicated in Results. After stimulation, monolayers were washed twice with ice-cold phosphate-buffered saline and lysed in modified RIPA buffer (50 mM Tris, pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 1 mM NaF and one tablet of Protease Inhibitor Cocktail (Roche Molecular Biochemicals, Mannheim, Germany per 50 mL). The cell lysate was gently shaken on a rocker for 15 min at 4°C. The lysate was centrifuged at 14 000 g in a precooled centrifuge for 15 min and the supernatant fluid was immediately transferred to a fresh centrifuge tube, discarding the pellet. Protein concentration was determined by the Bradford method using bovine serum albumin as standard. Samples containing equal amounts of protein were subjected to 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE; 20 lg/ lane) and transferred to nitrocellulose membrane. Membranes were blocked with 5% non-fat dry milk for 1 h at room temperature (20°C) and rinsed three times in phosphate-buffered saline with 0.1% Tween 20. Then followed an incubation for 90 min at room temperature with specific antibodies against phosphorylated ERK1/2 [phospho-p44/42 MAPK (Thr202/Tyr204; 1 : 2000)] or against ERK1/2 [p44/42 MAPK (1 : 2000)]. After three rinses, membranes were further incubated for 90 min at room temperature with peroxidase-conjugated anti-mouse or anti-rabbit IgG (1 : 10 000, respectively). Membranes were washed three times and proteins were visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Immunoprecipitation
For immunoprecipitation, the cell lysate (500-1000 lg protein) was incubated with the antibodies for 4 h at 4°C and then with protein G-conjugated agarose beads overnight with constant shaking at 4°C. Immune complexes were washed three times with ice-cold RIPA buffer, denatured in Laemmli sample buffer and resolved by SDS-PAGE. Tyrosine phosphorylation or the presence of immunoprecipitated proteins was detected by protein immunoblotting as described. For immunoblot analysis of Grb2-associable proteins, agarose-conjugated GST-Grb2 fusion protein was mixed with constant shaking with cell lysate at 4°C for 16 h and washed with lysis buffer. Bound proteins were solubilized, resolved by SDS-PAGE and subjected to immunoblotting. When quantification became necessary, band intensity was quantified using a GS-800 Calibrated Densitometer (Bio-Rad Laboratories, Hercules, CA, USA) with Quantity One Quantification Software.
Statistics
Statistical evaluation was carried out using Student's t-tests and p < 0.05 was considered to be significant. Data are given as means ± SEM.
Results
Thrombin induces Pyk2 phosphorylation in astrocytes through PAR-1
We have reported that thrombin can time-dependently induce ERK1/2 phosphorylation in astrocytes with the maximal activation obtained at 5 min. This phosphorylation decreased gradually but persisted for up to 3 h (Wang et al. 2002b) . Pyk2 is assumed to be a factor upstream of ERK phosphorylation. To assess whether thrombin activates Pyk2 in addition to eliciting ERK1/2 phosphorylation, serum-starved astrocytes were stimulated with thrombin (1 U/mL) for varying lengths of time (5 min)2 h) followed by immunoprecipitation with anti-Pyk2 and immunoblotting with antipTyr antibody. Our results demonstrate that Pyk2 is expressed in primary astrocytes, which is in accordance with other studies (Cazaubon et al. 1997; Bajetto et al. 2001) . Furthermore, thrombin treatment caused a rapid and sustained increase in phosphorylation of Pyk2. The most pronounced effect was obtained at 5 min. The phosphorylation signal remained obvious for at least 120 min (Fig. 1a) which is similar to the time course of the ERK1/2 activation stimulated by thrombin (Wang et al. 2002b) , implying that Pyk2 may play an important role in the ERK/MAPK cascade.
To verify that activation of Pyk2 by thrombin was receptor-dependent and to determine which thrombin receptor subtype mediated this stimulation, we applied TRag, a potent (Feng et al. 1995) and specific PAR-1-activating peptide (Kawabata et al. 1999) , in our experiments. Consistent with our previous results, TRag induced Pyk2 Fig. 1 Time course of proline-rich tyrosine kinase 2 (Pyk2) activation by thrombin in rat astrocytes. Serum-starved astrocytes were exposed to (a) thrombin (1 U/mL) or (b) thrombin receptor agonist (TRag; 1 lM) for the time periods indicated. Phosphorylated Pyk2 was detected by immunoblotting (IB) with anti-phosphotyrosine monoclonal antibody, following immunoprecipitation (IP) with anti-Pyk2. Upper panel, phosphorylation of Pyk2; lower panel, equal loading of protein by detecting total Pyk2. The blots shown are representative of three separate experiments.
Thrombin signalling via Pyk2 1351 phosphorylation in a similar pattern to thrombin (Fig. 1b) . The involvement of PAR-3 and PAR-4 can be excluded because no Pyk2 phosphorylation signal could be observed with applications of specific peptides (500 lM) activating either PAR-3 or PAR-4 (data not shown). These results indicate that thrombin activates Pyk2 in astrocytes through PAR-1.
Ca
2+
-dependent Pyk2 activation in response to PAR-1 activation in astrocytes We have demonstrated that thrombin and TRag stimulate proliferation in astrocytes via the ERK1/2 pathway in a Ca 2+ -and PKC-dependent manner. In our previous study we investigated blockade of the upstream factors of Ca 2+ release from internal stores, such as PLC and inositol 1,4,5-trisphosphate (InsP 3 ) receptor and blockade of PKC activation. Both the inhibition of PKC and of Ca 2+ release have been shown to attenuate proliferation and ERK1/2 phosphorylation induced by thrombin and TRag (Wang et al. 2002b) .
In the present study, to clarify the role of Ca 2+ in thrombininduced Pyk2 phosphorylation, we applied the intracellular calcium chelator BAPTA-AM, the specific PLC inhibitor U73122 and the InsP 3 receptor antagonist 2-APB. We have previously shown that short-term stimulation with thrombin and TRag induced a rapid increase in intracellular Ca 2+ in astrocytes (Ubl and Reiser 1997) . This effect can be inhibited almost completely by U73122 and 2-APB (Wang et al. 2002b) . Similarly, in the present study we observed that pre-treatment with BAPTA-AM caused a 90% reduction in Ca 2+ response induced by thrombin and TRag (data not shown). These substances were also employed in the current assay. As presented in Fig. 2(a and b) , pre-incubation with BAPTA-AM or 2-APB substantially blocked the Pyk2 phosphorylation stimulated by thrombin and TRag. In addition, Pyk2 phosphorylation in response to thrombin and TRag was also inhibited by U73122 (Fig. 2c) . The requirement for Ca 2+ to activate Pyk2 in astrocytes was further confirmed by assessing Pyk2 phosphorylation following short-term stimulation with Ca 2+ ionophore A23187, as demonstrated in Fig. 2(a) . These results proved the Ca 2+ dependence for Pyk2 phosphorylation by PAR-1 activation.
PKC-dependent Pyk2 activation in response to PAR-1 activation in astrocytes The requirement of PKC activation in thrombin-induced Pyk2 phosphorylation was examined by pre-treatment with the PKC inhibitor GF109203X. The data presented in Fig. 3(a) show that GF109203X partially diminished thrombin-and TRag-induced Pyk2 phosphorylation. In that blot the differences were not as pronounced as the effect of 2-APB. Therefore, the density of the signal was quantified. The result of the statistical analysis shown in Fig. 3 (TRag)-evoked proline-rich tyrosine kinase 2 (Pyk2) phosphorylation in rat astrocytes. Serum-starved astrocytes were pre-incubated with (a) BAPTA-AM (50 lM), (b) 2-aminoethoxydiphenylborate (2-APB; 100 lM) or (c) U73122 (5 lM) for 10 min prior to 5 min stimulation with thrombin (1 U/mL) or TRag (1 lM). A 5-min exposure to A23187 (2 lM) was also tested (a). Phosphorylated Pyk2 was detected by immunoblotting (IB) with anti-phosphotyrosine monoclonal antibody following immunoprecipitation (IP) with anti-Pyk2. The blots shown are representative of at least three separate experiments. Fig. 3 Involvement of protein kinase C activation in thrombin-and thrombin receptor agonist (TRag)-evoked proline-rich tyrosine kinase 2 (Pyk2) phosphorylation in rat astrocytes. Serum-starved astrocytes were pre-incubated with GF109203X (1 lM) for 10 min prior to 5 min stimulation with thrombin (1 U/mL) or TRag (1 lM). A 10-min exposure to phorbol-12,13-dibutyrate (PDBu; 100 nM) was also tested. Phosphorylated Pyk2 was detected by immunoblotting (IB) with anti-phosphotyrosine monoclonal antibody following immunoprecipitation (IP) with anti-Pyk2. A representative blot from at least three separate experiments is shown in (a). In addition, bands were quantified by a densitometer. The amount of Pyk2 phosphorylation was normalized by referring to the total amount of Pyk2. Data shown in (b) represent the mean ± SEM of at least three experiments. *p < 0.05, **p < 0.01 versus the value of cells stimulated by protease-activated receptor (PAR)-1 agonist in the absence of GF109203X.
activator phorbol-12,13-dibutyrate (PDBu) also increased Pyk2 phosphorylation, as shown in Fig. 3(a) . Thus, our results are consistent with data obtained in other cell types showing that Pyk2 is activated by GPCRs through transient elevation in the cytoplasmic concentration of Ca 2+ and/or activation of PKC (Lev et al. 1995; Sabri et al. 1998; Wu et al. 2002) .
Thrombin stimulates the association of Pyk2 with Src and Grb2
In neuronal cells Pyk2 has been implicated in the mediation of calcium ionophore-and phorbol ester-stimulated ERK1/2 phosphorylation via a direct interaction with c-Src . To elucidate whether, in astrocytes, ERK1/2 activation induced by stimulation with thrombin or TRag is mediated through Src, firstly, astrocytes were pre-treated with the selective inhibitor of the Src kinase family, PP2. At 10 lM, PP2 significantly abrogated both thrombin-and TRag-induced ERK1/2 phosphorylation (Fig. 4a) , suggesting the involvement of Src in the PAR-1/ERK signalling cascades. Secondly, the activation of Src was detected by using a specific antibody which recognizes phospho-Src at Tyr418, an auto-phosphorylation site located in the kinase activation loop . Full catalytic activity of c-Src kinase requires phosphorylation of Tyr418. As presented in Fig. 4(b) , phosphorylation of Src at Tyr418 can be induced by 5 min stimulation with thrombin or TRag. This effect is inhibited by pre-incubation with PP2 as well, providing direct evidence that Src is activated by PAR-1 activation and plays a role in thrombin signalling in astrocytes.
Interestingly, as shown in Fig. 5(a) , we also observed an inhibition of thrombin-and TRag-induced Pyk2 phosphorylation by PP2, indicating that Src may interact concomitantly with Pyk2 upstream of ERK1/2 activation. It has been documented that the autophosphorylation of Pyk2 at Tyr402 creates a direct binding site for the SH2 domain of Src, leading to Src activation. These steps subsequently enable Src to phosphorylate Pyk2 within the carboxyl terminus at Tyr881 which promotes Grb2 binding (Blaukat et al. 1999) . It is likely that the blockade of Src kinase by PP2 prevents the phosphorylation of Pyk2 at Tyr881. To further clarify this issue, we applied antibodies which specifically recognize phospho-Pyk2 at either Tyr402 or Tyr881 in western blotting. Results shown in Fig. 5(b) indicate that Pyk2 autophosphorylation at Tyr402 was not affected by PP2 pre-incubation. However, Pyk2 phosphorylation at Tyr881 was dramatically ). All upper panels, phosphorylation of Pyk2; all lower panels, equal loading of protein by detecting total Pyk2. The blots shown are representative of at least three separate experiments.
Thrombin signalling via Pyk2 1353 attenuated by PP2, suggesting that Src can also enhance Pyk2 kinase activity.
The results above strongly imply that a signalling complex is formed following PAR-1 activation, i.e. Pyk2/Src/Grb2, which subsequently leads to ERK1/2 activation. In fact, Fig. 6(a) shows that, after thrombin and TRag stimulation, Pyk2 was detectable by immunoblotting with anti-Pyk2 in the immunoprecipitate of Src. To further examine this hypothesis, we performed coprecipitation experiments with a GST-Grb2 fusion protein followed by immunoblotting with antibodies against either Pyk2 or Src. As shown in Fig. 6(b) , treatment with thrombin and TRag induced association of Grb2 with both Pyk2 and Src. These results indicate that PAR-1 activation promotes the interaction of Src with Pyk2. These data provide evidence that activated Pyk2 may recruit the adapter proteins through Src and Grb2 for the subsequent signal transduction.
Besides the Pyk2/Src/Grb2 signalling complex formed following PAR-1 activation, we have also examined the possible interaction between Pyk2 and Shc. It has been reported that thrombin and the thrombin receptor peptide agonist stimulate a rapid and sustained tyrosine phosphorylation of Shc, as well as the formation of Shc-Grb2 complex in CCL39 cells (Chen et al. 1996) . In our study, we found that the interaction between Grb2 and Shc was significantly enhanced after PAR-1 activation (Fig. 6b) . However, no clear signal could be detected by using anti-Shc antibody in the immunoprecipitate of either Src or Pyk2 from cells which were stimulated with thrombin or TRag (data not shown).
This indicates that there is no strong direct association between Shc and Src or Pyk2.
Discussion
Previous studies from our laboratory indicated that thrombin induces proliferation in rat astrocytes through an ERK1/2 activation pathway which might be regulated by a Ca 2+ -dependent tyrosine kinase or kinases. Subsequently, we excluded the possibility that the epidermal growth factor receptor acts as such a tyrosine kinase (Wang et al. 2002b) . Here, we further investigated and characterized a Ca 2+ -dependent tyrosine kinase, Pyk2, which is responsive to thrombin stimulation in rat astrocytes.
Pyk2 has been reported to be expressed at high levels mainly in cells of neuronal original (Avraham et al. 1995; Sasaki et al. 1995) . In the present study we provide evidence that, in astrocytes, Pyk2 can be activated by thrombin stimulation. TRag, a synthetic specific agonist of PAR-1, induced a response resembling that of thrombin. However, no such Pyk2 phosphorylation can be induced by peptides activating PAR-3 or PAR-4. Along with previous observations reporting that thrombin, through PAR-1 receptor, acts as a signalling molecule for astrocytes to evoke intracellular Ca 2+ mobilization (Ubl and Reiser 1997; Ubl et al. 2000) , ERK1/2 phosphorylation and proliferation (Wang et al. 2002b) , these results indicate that PAR-1 is the predominant receptor mediating the cellular consequence of thrombin stimulation in astrocytes. Ca 2+ signalling has been implicated as an important growth signal in many cell types (Berridge et al. 1998; Martinez-Salgado et al. 2000) . In rat astrocytes an increase in intracellular Ca 2+ has been demonstrated to play an essential role in transducing the mitogenic signal from PAR-1 receptor to ERK1/2 activation (Wang et al. 2002b) . The results obtained from the present study suggest that both Ca 2+ -and PKC-dependent pathways mediate thrombin-induced phosphorylation of Pyk2. The Ca 2+ -dependence is demonstrated by several lines of experiment. Firstly, Pyk2 was rapidly phosphorylated in response to the Ca 2+ ionophore, A23187. Secondly, chelation of cytosolic Ca 2+ by pre-treatment with BAPTA-AM resulted in a significant inhibition of thrombininduced Pyk2 phosphorylation. Thirdly, Pyk2 phosphorylation was diminished by inhibition of PLC and antagonism of InsP 3 receptor which both block Ca 2+ release from internal pools evoked by PAR-1 activation. In summary, these data are consistent with the involvement of Ca 2+ in thrombininduced ERK1/2 phosphorylation in astrocytes, implying that Pyk2 acts as a linker between the Ca 2+ signal and ERK1/2 activation.
Pyk2 lacks a calmodulin-binding motif. Therefore, it cannot be activated either by Ca 2+ or calmodulin in vitro (Huckle et al. 1992; Earp et al. 1995; Wilm et al. 1996) and the mechanism by which the Ca 2+ signal activates Pyk2 remains to be defined. In addition to the Ca 2+ -dependence, thrombin-induced Pyk2 phosphorylation is also regulated by PKC in astrocytes, which is evidenced by the attenuation of Pyk2 phosphorylation by the selective PKC inhibitor GF109203X and by direct stimulation by PKC activator PDBu. This finding contrasts with some reports of PKC-independent Pyk2 activation in several cell types, including cardiac fibroblast (Murasawa et al. 1998) and human endothelial cells (Keogh et al. 2002) , but it is in accordance with other studies showing a requirement for both PKC and Ca 2+ (Lev et al. 1995; Sabri et al. 1998; Wu et al. 2002) . It seems that, following PAR-1 activation, the Ca 2+ and PKC pathways converge at the point of Pyk2 in rat astrocytes.
Since initial work on Pyk2 identified this protein as a link between GPCRs and MAPK activation (Lev et al. 1995) , it is tempting to speculate that Pyk2 activation may be involved in the thrombin-elicited ERK/MAPK pathway. Pyk2 may interact with another tyrosine kinase, Src, and adapter proteins like Grb2 for the subsequent ERK1/2 phosphorylation. Although Pyk2 lacks Src homology 2 and 3 domains (SH2 and SH3), it is known that the auto-phosphorylation of Pyk2 at Tyr402 creates a potential high-affinity binding site for the SH2 domain of Src, leading to Src activation and the formation of a Pyk2-Src signalling complex. Recruitment and activation of Src can further lead to tyrosine phosphorylation of Pyk2 at Tyr 881 to create a binding site for the SH2 domain of Grb2 (Blaukat et al. 1999) . In addition, Src may also tyrosine phosphorylate the adapter molecule Shc, resulting in its interaction with Grb2 (Yamaguchi et al. 1997) . Grb2 can then recruit the guanine nucleotide exchange factor Sos, leading to Ras activation and, ultimately, activation of ERK1/2 (Rocic et al. 2001) . It has been shown that dominant negative mutants of Pyk2 blocked the formation of the ShcGrb2 signalling complex and, consequently, MAPK activation in PC12 cells (Lev et al. 1995; Dikic et al. 1996) . In the present study, we have demonstrated that Pyk2 forms a complex with both Src and Grb2 in astrocytes in response to thrombin stimulation. In addition, Shc also binds to Grb2 to form another signalling complex for signal transduction. Inhibition of Src tyrosine kinase reduces both Pyk2 phosphorylation at Tyr881 and ERK1/2 phosphorylation following PAR-1 activation, implicating that Pyk2 and Src are intermediates upstream of ERK1/2 activation in astrocytes.
The proposed involvement of Pyk2 in signal transduction of thrombin-induced ERK activation is illustrated in Fig. 7 . Ca 2+ mobilization and PKC activation induced by PAR-1 activation result in phosphorylation of Pyk2 at Tyr402 which, in turn, creates a binding site for Src tyrosine kinase. Binding of Src to phosphorylated Tyr402 leads to Src activation, which is critical for phosphorylation of Pyk2 at Tyr881, and subsequent binding of adapter protein Grb2. A signalling complex, i.e. Pyk2/Src/Grb2, is then formed. This complex, which also interacts through Grb2 with Shc and Sos, transmits signals downstream of Pyk2 towards ERK/MAPK pathways.
Besides being a regulator for ERK1/2 activation, Pyk2 may also be connected to other downstream transducers, such as c-Jun N-terminal kinase (JNK), by recruiting other adapter proteins, such as p130
Cas and Crk (Blaukat et al. 1999) . However, this possibility seems to be cell typespecific and agonist-dependent, since work from our laboratory has shown that PAR-1 activation in rat astrocytes fails to induce JNK phosphorylation (Wang and Reiser, unpublished data) . Therefore, it is conceivable that thrombininduced Pyk2 phosphorylation is not coupled to JNK activation in rat astrocytes.
In summary, we have demonstrated the expression and activation of Pyk2 in rat astrocytes. We suggest that Pyk2 may represent the tyrosine kinase which links the PAR-1-dependent increase in cytosolic Ca 2+ and PKC activation to the Src tyrosine kinase-mediated ERK/MAPK pathway. Thrombin has been implicated in cellular events as diverse as neuroprotection and neurodegeneration in the brain (Striggow et al. 2000) . Thus, understanding the role of Pyk2 in thrombin signal transduction may provide insights into the mechanisms that regulate the cellular consequences elicited by thrombin in the CNS. and protein kinase C (PKC) activation, resulting in phosphorylation of Pyk2 and recruitment of Src tyrosine kinase and adapter protein growth factor receptor-bound protein (Grb)2, leading ultimately to extracellular signal-regulated kinase (ERK)1/2-mediated proliferation. The latter has been evaluated in detail recently (Wang et al. 2002b) . DAG, Diacylglycerol; IP 3 , inositol 1,4,5-trisphosphate; MAPK, mitogen-activated protein kinase; PLC, phospholipase C; Shc, adapter protein in the Ras (small GTPase) pathway; Sos, son of sevenless, Ras guanine nucleotide-releasing factor.
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